Home/Pipeline/TEQ102 (formerly TUB-010)

TEQ102 (formerly TUB-010)

Oncology (unspecified)

Preclinical/Phase 1Active

Key Facts

Indication

Oncology (unspecified)

Phase

Preclinical/Phase 1

Status

Active

Company

Oncoteq

About Oncoteq

Oncoteq AG is a privately held, AI-powered oncology biotech founded in 2022 and based in Zug, Switzerland. The company utilizes a proprietary AI platform to identify and develop promising but potentially overlooked oncology therapeutics, aiming to transform drug development by combining AI-driven insights with a flexible company-builder model. With a small team of over 10 employees and strategic backing from its parent company, Cureteq AG, Oncoteq is advancing a pipeline of three clinical-stage assets while actively engaging with partners and investors in the biotech ecosystem. Its strategy centers on driving assets beyond key value inflection points through targeted development and partnerships.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active